Myomo (NYSEAMERICAN:MYO) Releases Quarterly Earnings Results

Myomo (NYSEAMERICAN:MYO) released its earnings results on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09), FiscalAI reports. Myomo had a negative return on equity of 61.14% and a negative net margin of 28.86%.The firm had revenue of $11.35 million during the quarter, compared to analyst estimates of $10.40 million.

Here are the key takeaways from Myomo’s conference call:

• Record revenue and orders: Q4 revenue was $11.4M and full-year revenue was $40.9M (+26% YoY) with a record 241 MyoPro orders and recurring-sources rising to 42% of revenue, signaling stronger revenue mix and demand.
• Channel and referral traction: U.S. O&P channel hit >$1M in quarterly revenue (about 36 O&P units in Q4) and the MyoConnect referral program produced 100+ qualified candidates (referrals ≈10% of pipeline adds), supporting lower future customer acquisition costs.
• International mixed results: International revenue topped $2M in the quarter (Germany grew ~46%) but the China JV is on hold after the majority partner declared bankruptcy, creating both upside in Europe and near-term uncertainty in China.
• Profitability and reimbursement headwinds: Operating expenses rose 19% (driven by higher marketing), Q4 net loss widened to $3.8M and adjusted EBITDA was -$1.9M, while Medicare Advantage denials have pressured direct-billing volume and added appeals-related uncertainty.
• 2026 guidance and cost initiatives: Management guided 2026 revenue of $43–$46M, plans to halve cash burn, expects gross-margin improvement (mobile app removing laptop costs) and aims for recurring sources to approach ~50% of revenue, indicating a path to tighter cash control and operating leverage.

Myomo Price Performance

Myomo stock opened at $0.81 on Tuesday. The company has a current ratio of 2.49, a quick ratio of 2.10 and a debt-to-equity ratio of 0.17. The company has a fifty day simple moving average of $0.87 and a 200-day simple moving average of $0.93. The stock has a market cap of $31.19 million, a P/E ratio of -2.80 and a beta of 1.17. Myomo has a 12-month low of $0.64 and a 12-month high of $6.30.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets lowered their price objective on Myomo from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, November 21st. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $7.67.

Institutional Trading of Myomo

Hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd purchased a new stake in Myomo during the 4th quarter worth about $148,000. AQR Capital Management LLC boosted its position in shares of Myomo by 47.8% during the 4th quarter. AQR Capital Management LLC now owns 434,376 shares of the company’s stock worth $395,000 after acquiring an additional 140,427 shares in the last quarter. State Street Corp increased its holdings in shares of Myomo by 5.1% in the 4th quarter. State Street Corp now owns 399,853 shares of the company’s stock valued at $364,000 after acquiring an additional 19,563 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Myomo by 103.1% during the 4th quarter. Wells Fargo & Company MN now owns 38,707 shares of the company’s stock worth $35,000 after acquiring an additional 19,646 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Myomo during the 4th quarter worth about $64,000. 44.99% of the stock is currently owned by institutional investors and hedge funds.

About Myomo

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.